Glenmark Pharma Introduces New Drug For Type two Diabetes

Glenmark Pharmaceuticals Limited, a worldwide pharmaceutical firm focused on research, has launched the first triple-drug fixed-dose combination (FDC) of the widely used teneligliptin with dapagliflozin and metformin in India. This FDC, known as Zita DM, contains the DPP4 inhibitor teneligliptin (20mg), the SGLT2 inhibitor dapagliflozin (10mg), and metformin SR (500mg/1000mg) in a fixed dose. To enhance glycemic control in type 2 diabetic patients, it must be taken once daily on a prescription basis.

On the occasion of the launch, Alok Malik, president and business head - India formulations at Glenmark Pharma, stated, "India has the world's second-largest diabetic population, and type 2 diabetic patients here frequently face issues of uncontrolled haemoglobin A1C (HbA1Ci), beta cell dysfunction, which impairs insulin secretion, as well as other co-morbidities like weight gain." Diabetes management becomes challenging for these people as well as a problem for healthcare providers as a result.

We are happy to announce Zita DM, an innovative and economical anti-diabetic medicine that improves glycemic control in adult patients with high HbA1c and other co-morbidities, while also lowering major renal and cardiac side effects. With this strong profile, we are certain that Zita DM will improve patient adherence to chronic medications, as per Pharmabiz. Glenmark's Zita portfolios of medicines help around 1.75 million type 2 diabetes patients in India each year. Zita, the most comprehensive gliptin spectrum, now offers the promise of assisting type 2 diabetic patients at every step of their therapy with the launch of Zita DM. According to IQVIA sales statistics for the 12-month period ending August 2023 (MAT August 2023), the market for oral anti-diabetic medications in India is anticipated to be Rs. 12,522 crore, a 6.5% increase over the same time last year (MAT August 2022). According to the ICMR-INDIAB survey, the overall weighted prevalence of diabetes was 11.4% between October 17th, 2008 and December 17th, 2020.